ALLENA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Information

On September 29, 2021, Allena Pharmaceuticals, Inc. issued a press release to report that it has dosed the first patient in a second Phase 2a trial of ALLN-346, a novel, orally-administered, urate-degrading enzyme in development for the treatment of gout in patients with chronic kidney disease. A copy of the press release is filed herewith as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release of Allena Pharmaceuticals, Inc., dated September 29,
            2021.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses